预约演示
更新于：2025-09-11
Ketoprofen
酮洛芬
更新于：2025-09-11
概要
基本信息
原研机构 |
权益机构- |
最高研发阶段批准上市 |
首次获批日期 中国 (1986-01-01), |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C16H14O3 |
InChIKeyDKYWVDODHFEZIM-UHFFFAOYSA-N |
CAS号22071-15-4 |
关联
145
项与 酮洛芬 相关的临床试验NCT06912763
Reversing External-beam Radiotherapy-associated Fibrosis Syndrome: an Interventional Bayesian Adaptive Randomized-controlled Orphan Drug Platform Trial for Orodental Sequelae (Reverse-fibrose)
CTR20252551
酮洛芬贴剂治疗膝骨关节炎的多中心、随机、双盲、阳性药及安慰剂平行对照的Ⅲ期临床研究
CTR20251551
酮洛芬贴剂在健康人群中的生物等效性试验
100 项与 酮洛芬 相关的临床结果
登录后查看更多信息
100 项与 酮洛芬 相关的转化医学
登录后查看更多信息
100 项与 酮洛芬 相关的专利（医药）
登录后查看更多信息
9,495
项与 酮洛芬 相关的文献（医药）2025-12-31JOURNAL OF CHEMICAL ENGINEERING OF JAPAN
Development of Multi-Phase Solid Formation for Dissolution Enhancement of Higher Drug Loading Phase-Separated Melt
作者: Takiyama, Hiroshi ; Tumurbaatar, Bolor-Uyanga
The method of Multi-Phase Solid with Shear (MPSwS), which uses shear force to form multi-phase solids, was investigated to evaluate the effect of changing drug loadings on the dissolution performance of API.Dissolution results showed that the dissolution rate monotonically decreased when the drug loading exceeded a certain amountTherefore, a novel method was proposed to upgrade the MPSwS method and enhance the dissolution performance even with higher drug loading.The novel MPSwS&A method, which combined shear force and aeration, was used to form the pore structure in the solid.Dissolution results showed that the novel MPSwS&A method enhanced the dissolution rate.From the fractured surface of the solid, the pore structure caused by bubbles and the structure formed by fine crystalline particles were observedThese results suggest that the combination of shear force and aeration enhances API dissolution performance by the synergistic effects of forming micro and macro structures.
2025-12-01BIORESOURCE TECHNOLOGY
Transform waste into profit: Extract licorice residue fiber to load Zr-MOF as a promising adsorbent
Article
作者: Sheng, Kangjia ; Bao, Tao ; Gao, Yan ; Yao, Junjie ; Wang, Sicen ; Long, Jiao ; Zheng, Xinglong ; Jing, Wanghui
The research on the reuse of resources is crucial for achieving high-value utilization of traditional Chinese medicine (TCM). In this study, licorice residues were selected to extract fibers by alkaline hydrogen peroxide oxidation because of their high cellulose content and widespread use. The cellulose, hemicellulose and lignin content of obtained fibers were found to be 55 %, 8.2 % and 18.8 %, respectively. Immobilizing MOF-808 onto licorice residue fibers yields a composite material exhibiting enhanced adsorption capabilities. The synthesized material was employed to adsorb ketoprofen, naproxen and diclofenac sodium. The characterization results confirmed the successful modification. Adsorption performance experiments indicate that the adsorption behavior follows pseudo-second-order kinetic models and Langmuir isotherm. The adsorption is a process of rapid adsorption and slow equilibrium, showing satisfactory adsorption capacity. X-ray photoelectron spectroscopy and density functional theory calculation revealed that the sustained adsorption attributed to the synergy of π-π stacking, hydrogen bonding and coordination interaction. This study emphasizes the potential for reusing licorice residues and paves the way for the treatment of TCM residue after extracting active ingredients.
2025-11-01JOURNAL OF PHOTOCHEMISTRY AND PHOTOBIOLOGY A-CHEMISTRY
Effect of microplastics on the photodegradation of high-consumption drugs under simulated sunlight: The critical role of aging and reactive oxygen species
作者: Kalaronis, Dimitrios ; Kyzas, George Z. ; Bikiaris, Dimitrios N. ; Evgenidou, Eleni ; Lambropoulou, Dimitra A. ; Teknetzi, Aikaterini ; Vourlias, George
The main aim of this study was to examine the effect of polypropylene (PP), poly(ethylene terephthalate) (PET), and poly(lactic acid) (PLA) microplastics (MPs) on the photolytic degradation of a mixture of seven commonly used pharmaceuticals under simulated solar irradiation (SSL).The target mixture included four common antibiotics (metronidazole, trimethoprim, indomethacin, isoniazid), two non-steroidal anti-inflammatory drugs (diclofenac, ketoprofen), and one antihypertensive drug (valsartan).The selected MPs were aged using three different procedures: (i) SSL light, (ii) UV/H2O2, and (iii) Fenton reagent.The effect of MPs mass concentration was examined using only the pristine MPs, while the aging effect was evaluated for the three different aged MPs for each polymer type.The results demonstrated that the presence of MPs generally accelerates the photolytic degradation of the drugs, and increasing their concentration further enhances the reaction rate.Aging of the MPs also appeared to enhance the photodegradation of the selected pharmaceuticals.Among the various aging processes applied, UV/H2O2 had the greatest impact on surface alteration of the MPs and consequently, UV/H2O2-aged PET MPs exhibited the highest influence on the photolytic degradation of the drugs.To gain a deeper understanding of the mechanism behind the photolytic degradation of the examined pharmaceuticals, a systematic characterization of pristine and aged MPs was conducted using Fourier transformed IR spectroscopy (FTIR), XPS, and SEM-energy dispersive X-ray spectroscopy (SEM-EDX) techniques, which detected the formation of oxygen containing groups on the MPs' surfaces.Finally, scavenger experiments were also conducted to explore the formation and role of reactive oxygen species (singlet oxygen, superoxide anions, and hydroxyl radicals) in the degradation of the target compounds
100 项与 酮洛芬 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 肩周炎 | 日本 | 2007-08-06 | |
| 肌腱病 | 日本 | 2007-08-06 | |
| 肿胀 | 日本 | 1989-09-01 | |
| 镇痛 | 日本 | 1986-11-29 | |
| 炎症 | 日本 | 1986-11-29 | |
| 骨关节炎 | 美国 | 1986-01-09 | |
| 疼痛 | 美国 | 1986-01-09 | |
| 类风湿关节炎 | 美国 | 1986-01-09 | |
| 关节炎 | 中国 | 1986-01-01 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 椎间盘疾病 | 临床3期 | 中国 | 2025-09-10 | |
| 椎间盘疾病 | 临床3期 | 中国 | 2025-09-10 | |
| 腰痛 | 临床3期 | 中国 | 2025-09-10 | |
| 腰痛 | 临床3期 | 中国 | 2025-09-10 | |
| 腰肌劳损 | 临床3期 | 中国 | 2025-09-10 | |
| 腰肌劳损 | 临床3期 | 中国 | 2025-09-10 | |
| 肌痛 | 临床3期 | 中国 | 2025-09-10 | |
| 肌痛 | 临床3期 | 中国 | 2025-09-10 | |
| 肌筋膜疼痛综合征 | 临床3期 | 中国 | 2025-09-10 | |
| 肌筋膜疼痛综合征 | 临床3期 | 中国 | 2025-09-10 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | 60 | Extract of ginger+Intravenous ketoprofen (Extract of Ginger) | 顧淵廠壓願選憲觸淵觸(築構壓糧襯蓋蓋膚範廠) = 夢夢淵遞艱願獵窪網鹹 壓鬱願鬱遞膚衊築構衊 (襯衊廠衊選構憲糧淵鹽, 0.04) 更多 | - | 2020-04-07 | ||
Cellulose+Intravenous ketoprofen (Cellulose) | 顧淵廠壓願選憲觸淵觸(築構壓糧襯蓋蓋膚範廠) = 膚壓膚觸願鑰鑰構糧鬱 壓鬱願鬱遞膚衊築構衊 (襯衊廠衊選構憲糧淵鹽, 0.07) 更多 | ||||||
N/A | 14 | laboratory biomarker analysis+(RS)2-(3-benzoylphenyl)-propionic acid ((RS)2-(3-benzoylphenyl)-Propionic Acid) | 願壓製夢構網鹽艱構鹽 = 廠繭淵鹹鏇繭遞願壓觸 網積鏇齋鏇廠範艱憲淵 (範獵鹹鏇鹹願鏇壓齋鹹, 醖鬱構壓醖壓齋襯網願 ~ 醖觸構鹹遞築遞繭願糧) 更多 | - | 2017-05-18 | ||
placebo for study drug (Placebo for Study Drug) | 願壓製夢構網鹽艱構鹽 = 製積鏇鹽鏇齋構網簾襯 網積鏇齋鏇廠範艱憲淵 (範獵鹹鏇鹹願鏇壓齋鹹, 積觸築憲廠獵簾鏇鹹簾 ~ 鑰鹽鬱範鹹網鬱構鹹齋) 更多 | ||||||
临床2/3期 | 9 | (Medications) | 襯蓋顧願鏇窪積壓顧襯(夢製蓋製糧鬱製膚衊糧) = 選積範淵獵壓廠餘膚獵 構顧壓觸鑰鑰淵顧鹽鑰 (餘壓遞簾膚鏇積鏇餘鏇, 1.94) 更多 | - | 2016-07-15 | ||
placebo (Placebo) | 襯蓋顧願鏇窪積壓顧襯(夢製蓋製糧鬱製膚衊糧) = 餘壓顧獵願範膚網築淵 構顧壓觸鑰鑰淵顧鹽鑰 (餘壓遞簾膚鏇積鏇餘鏇, 2.3) 更多 | ||||||
临床4期 | 340 | (Parecoxib) | 顧餘齋顧顧壓齋鏇構簾(遞鬱餘襯繭窪糧鹽製衊) = 遞鏇鹹廠簾淵醖獵醖餘 窪網膚觸繭醖願選鬱製 (夢鹹艱夢壓繭憲夢膚淵, 3.35) 更多 | - | 2013-01-28 | ||
(Ketoprofen) | 顧餘齋顧顧壓齋鏇構簾(遞鬱餘襯繭窪糧鹽製衊) = 鏇繭選範鑰構繭選選範 窪網膚觸繭醖願選鬱製 (夢鹹艱夢壓繭憲夢膚淵, 3.46) 更多 | ||||||
临床3期 | 866 | Placebo | 鏇憲蓋鑰襯鏇積廠廠艱(簾襯壓醖願鏇壓繭遞窪) = The majority of treatment related adverse events (AE) were dermal AE including erythema (8.6% with 100mg, 8.1% with 50mg, 3.6% with 25 mg ketoprofen and 4.5% with placebo). Other dermal AEs reported with a frequency ranging from 1-5% in any of the ketoprofen treatment groups included skin irritation, dry skin, eczema, contact dermatitis, pruritus and rash. Other AEs had an incidence rate below 1%. 壓壓蓋遞窪襯鹽糧鹽鑰 (餘艱夢構窪廠願願窪醖 ) | 积极 | 2007-06-13 | ||
25 mg ketoprofen in IDEA-033 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
Eureka LS:
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用